Select a Region
North America

Browsing Archive: Multiple SclerosisMultiple Sclerosis | EVERSANA

Posted on July 30, 20247/30/24

Predictive Modeling for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

EVERSANA
Posted on September 20, 20239/20/23

Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

EVERSANA
Posted on September 20, 20239/20/23

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

EVERSANA
Posted on February 1, 20232/1/23

Efficacy classification of modern therapies in multiple sclerosis

EVERSANA
Posted on February 1, 20232/1/23

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

EVERSANA
Posted on January 25, 20231/25/23

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.

EVERSANA
Posted on January 2, 20221/2/22

Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses

EVERSANA
Posted on October 2, 202010/2/20

The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis

EVERSANA
Posted on October 2, 202010/2/20

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple scelrosis

EVERSANA
Posted on October 2, 202010/2/20

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

Multiple Sclerosis